生命科學分析領域人工智慧市場規模、佔有率和成長分析：按組件、部署模式、應用、技術、最終用戶和地區分類——2026-2033年產業預測

2024 年全球生命科學分析領域的 AI 市值為 19 億美元，預計到 2025 年將成長至 20.8 億美元，到 2033 年將成長至 42.6 億美元，預測期（2026-2033 年）的複合年成長率為 9.4%。

生命科學分析領域人工智慧的成長主要得益於高通量生物數據的整合和機器學習技術的進步，從而能夠快速產生洞察並輔助決策。該市場涵蓋基因組學、蛋白質組學和臨床試驗等領域的演算法驅動型軟體和服務，能夠加速標靶發現和藥物重定位，同時最佳化患者分層。縮短從實驗室到患者的治療方法部署時間和成本，有助於改善患者預後，並增強生物製藥公司的競爭力。隨著資料互通性和多模態態整合變得至關重要，各機構正在利用多樣化的資料流來提高預測模型的準確性。對先進分析流程和聯邦學習的投資正在加速患者發現，最大限度地減少臨床試驗失敗，並促進夥伴關係關係的建立，從而推動生物製藥領域對可操作洞察和系統的需求。

生命科學分析領域人工智慧市場的全球促進因素

生物醫學和臨床資料集的快速成長顯著增強了生命科學分析領域人工智慧開發、檢驗和部署的基礎。隨著各種體學數據、影像數據和電子健康記錄數據的日益豐富，人工智慧模型能夠識別複雜模式的能力不斷提升，從而提高了預測能力。易於存取的資料儲存庫和協作共用舉措正在消除訓練大規模模型的障礙，並簡化轉換研究流程。由於人工智慧模型能夠利用更廣泛、更高品質的輸入數據，各機構對利用人工智慧進行科學發現和提升營運效率越來越有信心，這進一步推動了研發舉措的投資和整合。

生命科學分析領域全球人工智慧市場面臨的限制因素

人們日益關注患者隱私、數據所有權以及監管標準合規性問題，阻礙了關鍵臨床和基因組數據的收集和傳播，而這些數據對於建立有效的AI模型至關重要。嚴格的知情同意要求、各地區不同的隱私法規以及機構謹慎的態度，往往限制了對多樣化、高品質資料集的存取。這種限制對模型的泛化能力產生了負面影響，並使機構間檢驗變得困難。因此，尋求實施AI驅動分析的機構面臨專案管治複雜性增加、合作專案週期延長以及營運成本上升等問題。最終，這種情況會降低AI的普及速度，並限制研究合作的潛力。

全球人工智慧市場在生命科學領域的趨勢分析

全球生命科學分析領域的人工智慧市場正經歷著向多組體學整合的顯著轉變，這主要得益於演算法能力的提升和多樣化資料集的整合。生命科學領域的機構正優先考慮能夠有效整合基因組學、蛋白質組學、代謝體學和臨床數據的平台，以增強生物標記的發現和路徑建模。這一變革性趨勢正在減少孤立的分析，促進跨學科合作，並有助於產生更豐富的假設。隨著對標準化流程和互通工具的日益重視，整合分析的應用正在研發部門迅速擴展，顯著縮短了轉化研究的時間，並透過闡明複雜的生物學關係來增強目標檢驗。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球生命科學分析領域人工智慧市場規模：按組件分類

• 軟體平台
• 服務

全球生命科學分析領域人工智慧市場規模：按部署模式分類

• 基於雲端的
• 現場

全球生命科學分析領域人工智慧市場規模：按應用領域分類

• 藥物發現與開發
• 臨床試驗分析
• 精準醫療分析
• 基因組學和蛋白​​質組學分析
• 藥物警戒與藥物安全性分析
• 銷售、行銷與分析
• 供應鏈商業分析
• 其他用途

全球生命科學分析領域人工智慧市場規模：按技術分類

• 機器學習
• 深度學習
• 自然語言處理（NLP）
• 電腦視覺
• 其他人工智慧技術

全球生命科學分析領域人工智慧市場規模：按最終用戶分類

• 製藥公司
• 生技公司
• 受託研究機構（CRO）
• 學術研究機構
• 醫療服務提供方
• 其他最終用戶

全球生命科學分析領域人工智慧市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• IQVIA
• Tempus AI
• Schrodinger
• Certara
• Insilico Medicine
• BenevolentAI
• Exscientia
• Recursion Pharmaceuticals
• PathAI
• Owkin
• NVIDIA
• Microsoft
• Google
• Oracle
• SAS Institute
• Databricks
• Palantir Technologies
• Cytel
• DNAnexus
• Medidata Solutions

結論與建議

Global Ai In Life Science Analytics Market size was valued at USD 1.9 Billion in 2024 and is poised to grow from USD 2.08 Billion in 2025 to USD 4.26 Billion by 2033, growing at a CAGR of 9.4% during the forecast period (2026-2033).

The growth of AI in life science analytics is primarily driven by the integration of high-throughput biological data and advancements in machine learning, facilitating rapid insight generation and decision-making. This market includes software and services leveraging algorithms in genomics, proteomics, and clinical trials, enhancing target discovery and drug repurposing while optimizing patient stratification. The reduction of time and costs in translating therapies from laboratory to patient correlates with better patient outcomes and greater biopharma competitiveness. As data interoperability and multimodal integration become essential, organizations are harnessing diverse data streams to improve predictive models. Investment in advanced analytics pipelines and federated learning is accelerating patient discovery, minimizing trial failures, and fostering partnerships that enhance actionable insights and system demand in the biopharma sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ai In Life Science Analytics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ai In Life Science Analytics Market Segments Analysis

Global ai in life science analytics market is segmented by component, deployment mode, application, technology, end user and region. Based on component, the market is segmented into Software Platforms and Services. Based on deployment mode, the market is segmented into Cloud-Based and On-Premises. Based on application, the market is segmented into Drug Discovery & Development, Clinical Trial Analytics, Precision Medicine Analytics, Genomics & Proteomics Analytics, Pharmacovigilance & Drug Safety Analytics, Sales & Marketing Analytics, Supply Chain & Commercial Analytics and Other Applications. Based on technology, the market is segmented into Machine Learning, Deep Learning, Natural Language Processing (NLP), Computer Vision and Other AI Technologies. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes, Healthcare Providers and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ai In Life Science Analytics Market

The rapid growth of biomedical and clinical datasets has significantly enhanced the groundwork for the development, validation, and implementation of artificial intelligence in life science analytics. The increasing availability of diverse omics, imaging, and electronic health record data allows AI models to recognize intricate patterns, thereby enhancing their predictive capabilities. Accessible data repositories and collaborative sharing initiatives eliminate obstacles to training expansive models, streamlining translational research endeavors. As AI models harness a wider range of high-quality data inputs, organizations become more confident in leveraging AI for scientific discoveries and operational efficiencies, which further stimulates investment and integration within research and development initiatives.

Restraints in the Global Ai In Life Science Analytics Market

Growing worries about patient privacy, data ownership, and adherence to regulatory standards hinder the collection and dissemination of vital clinical and genomic data essential for effective AI model creation. Stringent consent requirements, differing regional privacy regulations, and a cautious approach from institutions often restrict access to varied and high-quality datasets. This restriction negatively impacts the generalizability of models and complicates cross-institutional validation. As a result, project governance becomes more complex, collaborative timelines are extended, and operational expenses increase for organizations trying to adopt AI-powered analytics. Consequently, this situation slows down adoption rates and limits the potential for research collaborations.

Market Trends of the Global Ai In Life Science Analytics Market

The Global AI in Life Science Analytics market is witnessing a notable shift towards multi-omics integration, driven by advancements in algorithmic capabilities and the harmonization of diverse datasets. Organizations in the life sciences are prioritizing platforms that effectively combine genomic, proteomic, metabolomic, and clinical data to enhance biomarker discovery and pathway modeling. This transformative trend is reducing siloed analyses, fostering interdisciplinary collaboration, and facilitating richer hypothesis generation. As the focus on standardized processes and interoperable tools intensifies, the adoption of integrated analytics is expanding across research and development functions, significantly shortening translational timelines and enhancing target validation through the elucidation of complex biological relationships.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global AI In Life Science Analytics Market Size by Component & CAGR (2026-2033)

• Market Overview
• Software Platforms
• Services

Global AI In Life Science Analytics Market Size by Deployment Mode & CAGR (2026-2033)

• Market Overview
• Cloud-Based
• On-Premises

Global AI In Life Science Analytics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Drug Discovery & Development
• Clinical Trial Analytics
• Precision Medicine Analytics
• Genomics & Proteomics Analytics
• Pharmacovigilance & Drug Safety Analytics
• Sales & Marketing Analytics
• Supply Chain & Commercial Analytics
• Other Applications

Global AI In Life Science Analytics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Machine Learning
• Deep Learning
• Natural Language Processing (NLP)
• Computer Vision
• Other AI Technologies

Global AI In Life Science Analytics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Healthcare Providers
• Other End Users

Global AI In Life Science Analytics Market Size & CAGR (2026-2033)

• North America (Component, Deployment Mode, Application, Technology, End User)
  • US
  • Canada
• Europe (Component, Deployment Mode, Application, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Component, Deployment Mode, Application, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Component, Deployment Mode, Application, Technology, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Component, Deployment Mode, Application, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• IQVIA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus AI
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Schrodinger
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Certara
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BenevolentAI
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exscientia
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recursion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PathAI
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Owkin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NVIDIA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microsoft
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Google
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oracle
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SAS Institute
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Databricks
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Palantir Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytel
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DNAnexus
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medidata Solutions
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations